The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Themis will market this drug with the brand name REMITHEM.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)